เปรียบเทียบวิธี

	ดัชนีการทำงานของโรคข้อกระดูกสันหลังอักเสบยึดติดบาธ (BASFI)	คะแนนกิจกรรมโรคข้อ 28 ข้อ (DAS28)	การประเมินข้อมูลผู้ป่วยตามปกติ 3 (RAPID3)
สาขาวิชา	วิทยาโรคข้อ	วิทยาโรคข้อ	วิทยาโรคข้อ
ตระกูล	Process / pipeline	Process / pipeline	Process / pipeline
ปีกำเนิด	1994	1995	2008
ผู้ริเริ่ม	Calin et al.	Prevoo et al.	Pincus et al.
ประเภท	Patient-reported outcome (PRO)	Clinician-rated	Patient-reported outcome (PRO)
แหล่งต้นตำรับ	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236.
ชื่อเรียกอื่น	BASFI, BAS-FI	DAS28, DAS28-CRP, DAS28-ESR	RAPID3, RAPID-3
ที่เกี่ยวข้อง	4	3	3
สรุป	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring.